BOSTON (Reuters) – Dicerna Pharmaceuticals Inc on Friday said that it will pay $15 million plus stock to Alnylam Pharmaceuticals Inc to resolve a lawsuit claiming it stole trade secrets about gene-silencing technology used to develop drug treatments.

No responses yet

Leave a Reply

Your email address will not be published. Required fields are marked *